Mevion’s European expansion gains momentum with Southern Italy proton therapy project
Proton therapy is precise but hard to scale. Mevion’s Naples win tests whether compact systems can shift access across Southern Europe.
Can Mevion’s S250-FIT make proton therapy practical for more cancer centers?
Proton therapy has long had an infrastructure problem. Mevion’s S250-FIT asks whether existing LINAC vaults can change that.
Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth
Sensus settled the dispute, but the harder test is SRT adoption. Can reimbursement momentum turn into durable medtech growth?
Can KUBTEC Scientific lower the barrier to image-guided radiotherapy in cancer research?
Preclinical IGRT is powerful but costly. KUBTEC Scientific’s XCELL TomoRad tests whether access, speed, and targeting can finally align.
How UNC Health’s Mevion deployment reflects a reset in proton therapy economics
UNC Health selects Mevion’s compact proton system. Discover what this means for proton therapy economics, workflows, and academic cancer care.
Proton therapy delivers survival gain in head and neck cancer: Could this Lancet trial shift payer and policy resistance?
A new phase III clinical trial published in The Lancet has shown that proton therapy significantly improves overall survival and reduces treatment-related toxicities in patients with oropharyngeal cancers compared to traditional photon-based radiation. Conducted across 21 U.S. institutions and led by researchers at the University of Texas MD Anderson Cancer Center, the study is the […]